AtriCure Boosts Atrial Fibrillation Treatment with the Launch of AtriClip and cryoSPHERE+ Probe
MASON, Ohio - AtriCure, Inc. (Nasdaq: ATRC), a pioneering medical technology company specializing in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, has announced the launch of two innovative products - AtriClip and cryoSPHERE+ cryoablation probe. These developments mark significant advancements in the field of cardiovascular surgery, offering improved treatment options and patient outcomes.
The AtriClip device, designed for Afib and LAA management, provides surgeons with a unique solution to reduce the risk of strokes caused by blood clots forming in the LAA. The device, made of a flexible titanium panel, is easily clamped onto the LAA, safely occluding it and preventing the formation of clots. This technology presents a breakthrough in the prevention of strokes associated with Afib, allowing patients to reduce their reliance on blood thinning medications.
The launch of AtriClip underscores our commitment to revolutionizing cardiovascular surgery and improving patient outcomes, said Michael Carrel, CEO of AtriCure. By providing physicians with a superior option to manage LAA effectively and minimize the risk of strokes, we are taking a significant step in combating the growing global burden of atrial fibrillation.
The cryoSPHERE+ cryoablation probe is another groundbreaking product from AtriCure, offering enhanced post-operative pain management. This innovative device utilizes new insulation technology, resulting in a 25% reduction in freeze times compared to AtriCure’s previous cryoSPHERE device. This shorter freezing time translates to less discomfort for patients and reduced recovery periods after surgery.
We are excited about the launch of cryoSPHERE+ as it addresses a critical unmet need in surgical post-operative pain management, noted Carrel. By optimizing freeze times, we are enabling patients to experience faster recovery and improved quality of life, underscoring our commitment to providing comprehensive solutions for cardiovascular care.
Both the AtriClip and cryoSPHERE+ are currently in an extended limited launch period in the United States, with plans for wider distribution in the near future. These products have demonstrated remarkable potential in improving surgical outcomes, reducing patient discomfort, and reducing healthcare costs associated with complications.
The introduction of these cutting-edge technologies solidifies AtriCure’s position as a pioneer in the field of cardiovascular surgery. With their advanced solutions for Afib, LAA management, and post-operative pain management, the company is redefining the standard of care and improving the lives of patients worldwide.
Comments